Data from Pharmawand - Curated by Toby Galbraith - Date added 05 July 2012

Takeda and Millennium Oncology have begun a Phase III development programme for ixazomib citrate (MLN 9708), the first oral proteasome inhibitor to enter clinical trials for Multiple Myeloma and to be a possible successor to the Velcade. The trial is TOURMALINE-MM1 which will assess MLN 9708 in patients with relapsed and/or refractory Multiple Myeloma at sites in North and South America, Europe and the Asia-Pacific region. A once weekly dose will be administered in combination with lenalidomide and dexamethasone therapy and compared with placebo plus the latter two drugs against the primary endpoint of progression-free survival.Ixazomib has improved and broader activity and pharmacokinetics compared with Velcade which is intravenously administered whereas Ixazomib is orally administered.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria

+ 3 more

Visit Chronic Spontaneous Urticaria (CSU)

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress.

Visit IL-17A in Psoriasis

Related Content